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Introduction: Soluble urokinase-type plasminogen activator receptor (suPAR) strongly predicts outcomes
and incident chronic kidney disease (CKD) in patients with cardiovascular disease (CVD). Whether the
association between suPAR and CKD is a reﬂection of its overall association with chronic inﬂammation
and poor CVD outcomes is unclear. We examined whether CVD biomarkers, including high-sensitivity
C-reactive protein (hs-CRP), ﬁbrin-degradation products (FDPs), heat-shock protein 70 (HSP-70), and
high-sensitivity troponin I (hs-TnI) were associated with a decline in kidney function in the Emory
Cardiovascular Biobank cohort, in which suPAR levels were shown to be predictive of both incident CKD
and CVD outcomes.
Methods: We measured suPAR, hs-CRP, HSP-70, FDP, and hs-TnI plasma levels in 3282 adults (mean age
63 years, 64% male, 75% estimated glomerular ﬁltration rate [eGFR] >60 ml/min per 1.73 m2). Glomerular
ﬁltration rate was estimated using Chronic Kidney Disease–Epidemiology Collaboration (eGFR) at enroll-
ment (n ¼ 3282) and follow-up (n ¼ 2672; median 3.5 years). Urine protein by dipstick at baseline was
available for 1335 subjects.
Results: There was a weak correlation among biomarkers (r range: 0.170.28). hs-CRP, FDPs, hs-TnI, and
suPAR were independently associated with baseline eGFR and proteinuria. The median yearly decline in
eGFR was 0.6 ml/min per 1.73 m2. hs-CRP (b: 0.04; P ¼ 0.46), FDPs (b: 0.13; P ¼ 0.08), HSP-70 (b: 0.05;
P ¼ 0.84), or hs-TnI (b: 0.01; P ¼ 0.76) were associated with eGFR decline. suPAR remained predictive of
eGFR decline even after adjusting for all biomarkers.
Discussion: hs-CRP, FDP, HSP-70, and hs-TnI were not associated with eGFR decline. The speciﬁc
association of suPAR with eGFR decline supported its involvement in pathways speciﬁc to the
pathogenesis of kidney disease.
Kidney Int Rep (2017) 2, 425–432; http://dx.doi.org/10.1016/j.ekir.2017.02.001
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C hronic kidney disease (CKD), which is deﬁned as areduced glomerular ﬁltration rate (GFR), affects
>14% of the US population and has been steadily
increasing in incidence and prevalence.1 Patients with
CKD are at high risk of cardiovascular disease (CVD) and
mortality.1,2 Despite the overall improvement in car-
diovascular outcomes over the past few decades, there
has been negligible progress in identifying patients at
risk of CKD.1 Current methods for screening for kidney
disease are limited, and rely on the measurement of
proteinuria and estimation of GFR, which are both
reﬂective of active kidney injury rather than risk.3–6
Recently, we identiﬁed soluble urokinase-type
plasminogen activator receptor (suPAR) as an
important predictor of incident CKD in patients
with CVD.7 suPAR is the circulating form of
a glycosyl-phosphatidylinositolanchored 3-domain
membrane protein expressed on a variety of cells,
including immunologically active cells, endothelial
cells, and podocytes8–10; it has been implicated in the
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pathogenesis of various forms of kidney disease.9,11–15
Elevated suPAR levels are strongly predictive of poor
cardiovascular outcomes and are associated with endo-
thelial dysfunction, increased vascular stiffness, and
atherosclerosis.16–20
Other biomarkers of CVD and inﬂammation have
been previously associated with kidney disease.3,21
High-sensitivity C-reactive protein (hs-CRP) is elevated
in patients with CKD22 and is associated with worse
outcomes in this population.23 Studies that have exam-
ined the association between hs-CRP and progression of
kidney disease have been conﬂicting.24,25 Heat shock
protein-70 (HSP-70), a marker of cellular stress, is
believed to be involved in the regulation of oxidative
stress and pathogenesis of CKD.26 Fibrin degradation
products (FDPs) are elevated in patients with CKD and
reﬂect a hypercoagulable state associated with increased
cardiovascular risk.27 Lastly, high-sensitivity troponin-I
(hs-TnI), despite being higher in patients with CKD due
to reduced clearance, remains predictive of CVD out-
comes.28 Whether these markers are predictive of inci-
dent decline in renal function and whether the
association between suPAR and estimated GFR (eGFR)
decline is independent of the aforementioned CVD bio-
markers is unclear. We examined whether hs-CRP,
FDPs, HSP-70, and hs-TnI are associated with eGFR
decline in the Emory Cardiovascular Biobank, the cohort
in which suPAR levels were shown to be predictive of
incident CKD and CVD outcomes.7,17,29 We hypothe-
sized that only suPAR would be associated with future
eGFR decline and that the association would be inde-
pendent of hs-CRP, HSP-70, FDP, and hs-TnI levels.
METHODS
The study is presented following the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) Statement checklist for cohort studies (www.
strobe-statement.org).30
Study Design and Population
We measured suPAR, hs-CRP, HSP-70, FDP, and
hs-TnI plasma levels in 3282 adult patients who un-
derwent left heart catheterization for suspected or
conﬁrmed coronary artery disease (CAD) at 3 Emory
Healthcare sites from 2003 to 2014, and who were
enrolled in the Emory Cardiovascular Biobank.17
Exclusion criteria included congenital heart disease,
severe valvular heart disease, severe anemia, recent
blood transfusion, myocarditis, or history of active
inﬂammatory disease and cancer. Patients were inter-
viewed to collect demographic characteristics, medical
history, and medication use. Medical records were
reviewed to conﬁrm self-reported medical history.
The average discrepancy across variables between
self-reported medical history and electronic medical
record review was 6.6%. In the event of a discrepancy
between self-reported history of electronic medical re-
cord documentation, we adopted the version denoting
the presence of disease. All available measures of eGFR
and urine protein performed at Emory Healthcare sites
were collected. The study was approved by the Insti-
tutional Review Board at Emory University (Atlanta,
GA), and conducted according to the Declaration of
Helsinki. All patients provided written informed con-
sent at the time of enrollment.
We ﬁrst examined the association between baseline
biomarker levels and measures of kidney function
(eGFR and semi-quantitative assessment of proteinuria).
We then investigated the association between suPAR,
hs-CRP, HSP-70, FDP, and hs-TnI plasma levels and
change in eGFR during follow-up in 2672 (81%) pa-
tients with at least 1 additional measure of eGFR (me-
dian number of measurements: 7) during a median
follow-up of 3.5 years (Figure S1).
Sample Collection and Biomarker
Measurements
Fasting arterial blood samples were collected and serum
and plasma stored at 80C for a mean duration of
4.9 years. Serum hs-CRP concentrations were deter-
mined using a particle-enhanced immunoturbidimetry
assay with a lower detection limit of 0.03 mg/L (First-
Mark, Division of GenWay Biotech Inc, San Diego,
CA).31 Plasma levels of suPAR were measured by
Virogates (suPARnostic kit; Copenhagen, Denmark).
FDP levels were determined using a sandwich immu-
noassay. FDP components included fragments D and E,
D-dimer, and additional intermediate cleavage
products. HSP-70 was measured with a sandwich
enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, Minnesota) and optimized by FirstMark.
Minimum detectable suPAR, hs-CRP, FDP, HSP70, and
hs-TnI concentrations were 100 pg/ml, 0.1 mg/L, 0.06
mg/ml, 0.625 ng/ml, and 0.3 pg/ml, respectively.
Measures of Kidney Function
Serum creatinine measurements at enrollment and all
subsequent values acquired during routine follow-up
clinic visits or hospitalizations within the Emory
Healthcare system were collected. eGFR was calculated
using the chronic kidney disease-EPI equation.32 Semi-
quantitative random urine protein excretion by
dipstick testing was available for 1355 patients at the
time of enrollment.
Statistical Analysis
Continuous variables are summarized as means  SD
or as median (interquartile range), and categorical
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variables as proportions (percent). Independent t-tests
or Wilcoxon rank-sum tests and c2 tests were used to
compare continuous and categorical variables, respec-
tively. Proteinuria data were available in a subset of
patients (n ¼ 1355) and were dichotomized as “no
proteinuria,” which included negative or trace, and
“proteinuria” (n ¼ 109), which included grades $1þ.
eGFR values >120 ml/min per 1.73 m2 (<1% of mea-
surements) were set at 120 ml/min per 1.73 m2. The
associations between each biomarker and eGFR at
baseline were initially evaluated using Spearman’s
correlation. Logistic regression was used to examine the
association between each biomarker and proteinuria.
The association between baseline biomarker levels and
change in eGFR over time was investigated using linear
regression in 2672 patients with follow-up eGFR mea-
surements. We regressed the follow-up eGFR values on
baseline biomarker levels, follow-up time (years since
baseline), and interactions between biomarkers and
follow-up time. suPAR, hs-CRP, FDPs, and hs-TnI were
log-transformed (base 2) in all regression models, such
that the interpretation was eGFR decline per 100%
increase in the biomarker, whereas HSP-70 was exam-
ined as a categorical variable (HSP-70 $1 ng/ml). All
models included the following covariates: age, sex, race
(blacks vs. others), body mass index, history of
smoking, hypertension, diabetes, low-density lipopro-
tein, high-density lipoprotein, history of myocardial
infarction, history of revascularization, presence of
obstructive coronary artery disease, heart failure, and
use of renin-angiotensin system inhibitors. The cova-
riates were chosen a priori due to potential confound-
ing effects on the relationship between suPAR and
eGFR, based on the known association between the
chosen variables and suPAR, the other biomarkers, or
renal function.7,17,18,29 Missing eGFR data were
assumed to be missing at random, and were handled via
maximum likelihood estimation. The ﬁxed-effects
models with autoregressive-1 correlation structure
(chosen based on smallest Akaike information criterion
value) were used to account for within-subject corre-
lations in repeated eGFR measurements. Two-tailed
P values #0.05 were considered statistically signiﬁ-
cant. All analyses were performed using SAS 9.3
(SAS Institute, Cary, NC).
RESULTS
Cohort Characteristics
Demographic and clinical characteristics of the total
cohort, stratiﬁed according to baseline eGFRs are
shown in Table 1. Overall, the cohort consisted of a
majority of men (64%) and Caucasians (82%), with at
least two-thirds having obstructive coronary artery
disease at enrollment. Seventy-ﬁve percent of subjects
had an eGFR >60 ml/min per 1.73 m2. Less than 10%
had at least 1þ proteinuria by dipstick testing. In
multivariable analyses, a lower eGFR at baseline was
independently associated with increasing age, male
gender, hypertension, diabetes mellitus, higher
low-density lipoprotein levels, lower high-density
lipoprotein levels, heart failure, and use of renin-
angiotensin system inhibitors (Table 2). Proteinuria
was independently associated with African American
race, diabetes mellitus, and heart failure (Table 2).
CVD Biomarkers and Kidney Function at
Baseline
Decreasing eGFR was associated with increasing levels
of suPAR, hs-CRP, FDPs, and hs-TnI (Tables 1 and 3).
Patients with lower eGFRs were more likely to have
HSP-70 levels $1 ng/ml. We found a signiﬁcant
negative correlation between all 5 biomarkers and
eGFR, with suPAR levels having the strongest corre-
lation with eGFR (r ¼ 0.42; P < 0.001), and hs-CRP
and HSP-70 having the weakest correlations
(r ¼ 0.05 and r ¼ 0.07; P < 0.001, respectively)
(Table 3). The correlation between the biomarkers was
weak (r range: 0.070.27). After adjusting for CVD and
CVD risk factors, suPAR (b: 13.55; P < 0.001),
hs-CRP (b: 0.72; P < 0.001), FDP (b: 0.97;
P < 0.001), and hs-TnI (b: 0.77; P < 0.001) were
independently associated with baseline eGFR. A 100%
higher suPAR (odds ratio [OR]: 3.00; P < 0.001),
hs-CRP (OR: 1.18; P ¼ 0.009), FDP (OR: 1.15;
P ¼ 0.023), and hs-TnI (OR: 1.12; P ¼ 0.004) level was
associated with at least þ1 proteinuria on dipstick
testing (Table 3).
CVD Biomarker Levels and eGFR Decline
We sought to determine whether hs-CRP, FDPs,
HSP-70, and hs-TnI were associated with eGFR decline,
and whether suPAR remained predictive of eGFR
decline after adjusting for all biomarkers. Overall, in
2672 patients in whom eGFR was measured during
follow-up, the median yearly decline in eGFR was
0.6 ml/min per 1.73 m2. Of 1935 subjects with base-
line eGFR $60 ml/min per 1.73 m2, 406 (21%) devel-
oped CKD stage III (eGFR <60 ml/min per 1.73 m2).
In unadjusted analyses, HSP-70 (b: 0.35; 95% con-
ﬁdence interval [CI]: 0.200.49) or hs-TnI (b: 0.02;
95% CI:  0.05 to 0.0002) were signiﬁcantly associ-
ated with eGFR decline, whereas hs-CRP (b: 0.03;
95% CI: 0.07 to 0.003), and FDP (b: 0.04; 95%
CI: 0.07 to 0.002) were not.
Table 4 shows the multivariable analysis results of
the associations between each of the biomarkers and
eGFR decline. Even when adding 1 biomarker to the
base model at a time, suPAR levels remained associated
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with eGFR decline (P < 0.001). Speciﬁcally, eGFR was
estimated to decrease by 0.42 (95% CI: 0.63 to 0.20)
a year per 100% increase in baseline suPAR level, even
after adjusting for clinical characteristics and hs-CRP,
FDP, HSP-70, and hs-TnI.
DISCUSSION
In this study, we characterized the association between
CVD biomarkers and kidney function in a prospective
cohort of adults with CVD. Although all 5 biomarkers,
suPAR, hs-CRP, FDPs, HSP-70, and hs-TnI, correlated
with measures of renal function cross sectionally, only
suPAR was associated with future decline in eGFR. The
importance of these ﬁndings is 2-fold: ﬁrst, we showed
that well-established biomarkers associated with CVD
and CKD did not predict future decline in eGFR, which
suggested that they were unlikely to be reﬂective of
pathways related to kidney disease, and thus, were not
useful in predicting incident renal dysfunction. Sec-
ond, suPAR, which we previously showed to be pre-
dictive of eGFR decline and outcomes in the same
cohort, remained associated with incident renal
dysfunction, ever after adjusting for clinical charac-
teristics, hs-CRP, FDPs, HSP-70, and hs-TnI, which are
all biomarkers that are independently and highly
predictive of CVD outcomes.7,17,29,33 Thus, the relation
between suPAR and eGFR decline goes beyond
reﬂecting overall worse clinical status and CVD
outcomes.
CKD and CVD are tightly linked and share common
risk factors and underlying pathophysiologic mecha-
nisms, including inﬂammation, oxidative stress, and a
pro-coagulant state.2,3 hs-CRP, as a measure of inﬂam-
mation, rises signiﬁcantly with declining renal func-
tion, and although it is strongly predictive of adverse
CVD outcomes in patients with CKD, the association
with incident renal disease has been inconsistent.24,25,34
In a substudy of the Justiﬁcation for the Use of Statins
in Prevention: an Intervention Trial Evaluating Rosu-
vastatin (JUPITER) trial, statins reduced CRP levels but
did not improve renal outcomes despite better
survival.35 FDPs are markers of hemostasis that were
associated with CKD and CVD mortality.27,36 Previous
studies also did not ﬁnd an association between eGFR
decline and FDPs.37,38 Elevations in HSP-70 typically
result as a counter-regulatory mechanism to cellular
stress, and are increased in several clinical conditions,
including CKD.26,39 Inhibition of HSP slowed renal
parenchymal ﬁbrosis in rats with obstructive
nephropathy.40 Although it was predictive of mortality
Table 1. Clinical characteristics and biomarker levels stratiﬁed by estimated glomerular ﬁltration rate
Variables Entire cohort (n [ 3282)
eGFR (ml/min per 1.73 m2)
P value>90 (n [ 782)a 60L89 (n [ 1670)b <15L59 (n [ 830)c
Age, yr 6312 5510 6410a 7011a,b <0.001
Male 2108 (64) 492 (63) 1132 (68)c 484 (58) <0.001
African American 604 (18) 217 (28)b,c 253 (15) 134 (16) <0.001
Body mass index, kg/m2 306 317b,c 306 296 0.001
Clinical characteristics
Smoking history 2165 (66) 494 (63) 1122 (67) 549 (66) 0.15
Hypertension 2366 (72) 515 (66) 1169 (70) 682 (83)a,b <0.001
Diabetes mellitus 1013 (31) 222 (28) 471 (28) 320 (39)a,b <0.001
Low-density lipoprotein, mg/dl 9737 10339)b,c 9836c 9136 <0.001
High-density lipoprotein, mg/dl 4213 4213 4212 4214 0.93
Myocardial infarction history 923 (28) 202 (26) 448 (27) 232 (28)a,b 0.005
Revascularization history 2039 (63) 427 (55) 1034 (62) 518 (62)a,b <0.001
Obstructive coronary artery disease 2149 (69) 439 (60) 1096 (69) 614 (79)a,b <0.001
Heart failure 513 (16) 80 (10) 228 (14) 205 (25)a,b <0.001
eGFR, ml/min per 1.73 m2 7422 1018b,c 759 4514 <0.001
Proteinuria $1þd 109 (8) 13 (5) 41 (6) 55 (7)a,b <0.001
ACEi/ARB use 1931 (59) 434 (56) 996 (60) 501 (60) 0.09
Biomarkers
SuPAR, pg/ml 3019 (2359, 3974) 2610 (2090, 3287) 2853 (2299, 3553) 4070 (3191, 5392) <0.001
Hs-CRP, mg/dl 3.05 (1.2, 7.6) 3.4 (1.3, 7.8) 2.5 (1.1, 6.4) 3.8 (1.5, 9.9) <0.001
FDP, mg/ml 0.54 (0.36, 0.84) 0.46 (0.32, 0.70) 0.52 (0.36, 0.78) 0.68 (0.45, 1.10) <0.001
HSP-70 $1 622 (19) 139 (18) 283 (17) 200 (24)a,b <0.001
Hs-Tn I, pg/ml 5.4 (2.9, 14.5) 3.8 (2.3, 10.2) 5.1 (2.8, 12.0) 9.1 (1.6, 26.4) <0.001
Obstructive coronary artery disease denotes the presence of at least 50% obstruction in any of the coronary arteries on angiogram.
Values are reported as meanSD or n (%). Biomarker levels are reported as median (25th, 7th percentiles). Statistically signiﬁcant values at P < 0.05 are highlighted in bold.
ACEi, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular ﬁltration rate; FDP, ﬁbrin degradation product; Hs-CRP, high-sensitivity C-reactive
protein; HSP-70, heat shock protein 70; hs-TnI, high sensitivity troponin I; suPAR, soluble urokinase-type plasminogen activator receptor.
a,b,cResults of pairwise comparisons using the Bonferroni correction are denoted as follows: for each significant pair, the key of the category (a, b, or c for each eGFR category) with the
smallest value appears in the category with the larger value.
dProteinuria data was available for 1335 patients.
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and CVD outcomes, we were the ﬁrst to show that
elevation in HSP-70 was not associated with future
eGFR decline in humans.29 Similarly, although hs-TnI
levels correlated with both eGFR and proteinuria and
were associated with adverse outcomes in both patients
with and without CKD, we found that its levels did not
predict eGFR decline.28 Various additional markers of
inﬂammation, such as interleukin-6 and intercellular
adhesion molecule-1 were also found not to be pre-
dictive of eGFR decline.37,38 These ﬁndings suggested
that conventional markers of inﬂammation that are
typically associated with the atherosclerotic process
and CVD outcomes might not represent a major driver
of kidney disease progression. Increased production,
decreased renal clearance, or a combination of both
mechanisms likely contributed to elevations of the
aforementioned biomarkers, including suPAR, in renal
insufﬁciency.12,41–43
The association between suPAR and kidney disease
was ﬁrst described in focal segmental glomerulo-
sclerosis.13 Although the debate is still ongoing as to
whether suPAR is merely a biomarker of the disease
rather than a causative agent in humans,12 there is
increasing evidence from mouse models that over-
express certain forms of suPAR, that a direct patho-
logical effect, induced by binding and activation of
Table 3. Spearman-Rank correlations between biomarkers and estimated glomerular ﬁltration rate
Characteristics
eGFR SuPAR Hs-CRP FDP HSP-70 Hs-TnI
R P value r P value r P value R P value r P value r P value
SuPAR L0.42 <0.001 0.27 <0.001 0.28 <0.001 0.17 <0.001 0.26 <0.001
Hs-CRP L0.05 0.003 0.27 <0.001 0.22 <0.001 0.07 <0.001 0.20 <0.001
FDP L0.23 <0.001 0.28 <0.001 0.22 <0.001 0.19, <0.001 0.24 <0.001
HSP-70 L0.07 <0.001 0.17 <0.001 0.07 <0.001 0.19 <0.001 0.04 0.30
Hs-TnI L0.24 <0.001 0.26 <0.001 0.20 <0.001 0.24 <0.001 0.04, 0.30 0.30
Statistically signiﬁcant values at P < 0.05 are highlighted in bold.
FDP, ﬁbrin degradation product; Hs-CRP, high-sensitivity C-reactive protein; HSP-70, heat shock protein 70; hs-TnI, high sensitivity troponin I; suPAR, soluble urokinase-type plasminogen
activator receptor.
Table 2. Independent predictors of glomerular ﬁltration rate and proteinuria at enrollment
Variables
eGFR (ml/min per kg/m2) ‡D1 Proteinuria
b 95% CI P value OR 95% CI P value
Model 1: Clinical characteristics
Age, per 10 yr L0.40 L8.12 to L6.65 <0.001 0.86 0.69 to 1.09 0.22
Male 0.09 2.39 to 5.89 <0.001 1.23 0.71 to 2.14 0.46
African American 0.00 1.99 to 2.21 0.92 2.93 1.72 to 4.98 <0.001
Body mass index, per 5 kg/m2 increase 0.01 0.83 to 0.51 0.64 0.98 0.81 to 1.19 0.84
Smoking history 0.01 2.10 to 1.21 0.60 0.98 0.58 to 1.67 0.95
Hypertension L0.08 L5.79 to L2.20 <0.001 1.74 0.87 to 3.50 0.12
Diabetes mellitus L0.04 L3.55 to L0.10 0.038 3.60 2.13 to 6.09 <0.001
Low-density lipoprotein, per 10 mg/dl 0.07 0.18 to 0.61 <0.001 0.99 0.93 to 1.06 0.8
High-density lipoprotein, per 10 mg/dl 0.04 0.04, 1.33 0.038 1.06 0.87 to 1.28 0.59
Myocardial infarction history 0.00 1.83 to 1.79 0.98 0.71 0.38 to 1.32 0.28
Revascularization history 0.02 1.72 to 3.08 0.58 0.67 0.35 to 1.29 0.23
Obstructive coronary artery disease 0.03 3.91, 1.16 0.29 1.39 0.67 to 2.87 0.38
Heart failure L0.12 L8.68 to L4.51 <0.001 1.90 1.10 to 3.31 0.023
ACEi/ARB use 0.07 1.32 to 4.61 <0.001 0.67 0.40 to 1.12 0.12
Model 27: Clinical characteristics þ individual biomarkers
SuPAR, per 100% increase L13.55 L14.83 to L12.27 <0.001 3.00 2.03 to 4.44 <0.001
Hs-CRP, per 100% increase L0.72 L1.14 to L0.30 <0.001 1.18 1.04 to 1.34 0.009
FDP, per 100% increase L0.97 L1.44 to L0.51 <0.001 1.15 1.02 to 1.29 0.023
HSP-70 $ 1 ng/ml 1.36 3.65 to 0.40 0.12 1.71 0.96 to 3.03 0.07
Hs-Tn I, per 100% increase L0.77 L1.08 to L0.46 <0.001 1.12 1.04 to 1.21 0.004
Model 8: Clinical characteristics þ all biomarkers
SuPAR, per 100% increase L13.57 L14.89 to L12.24 <0.001 2.67 1.79 to 3.99 <0.001
Hs-CRP, per 100% increase 0.36 0.05 to 0.76 0.09 1.04 0.91 to 1.20 0.54
FDP, per 100% increase L0.55 L0.99 to L0.11 0.015 1.07 0.94 to 1.23 0.31
HSP-70 > 1 ng/ml 1.36 0.54 to 3.26 0.16 1.43 0.77 to 2.65 0.26
Hs-Tn I, per 100% increase L0.38 L0.68 to L0.08 0.014 1.10 1.01 to 1.20 0.038
Biomarkers were each entered into separate models incorporating demographics and risk factors. The estimate, OR, and CI reported for the demographics and clinical characteristics
are derived from the model not incorporating any biomarkers. Statistically signiﬁcant values at P < 0.05 are highlighted in bold.
ACEi, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; FDP, ﬁbrin degradation product; Hs-CRP,
high-sensitivity C-reactive protein; HSP-70, heat shock protein 70; hs-TnI, high-sensitivity troponin I; OR, odds ratio; suPAR, soluble urokinase-type plasminogen activator receptor.
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podocyte avb3 integrin, in turn leads to activation of
the small GTPase Ras-related C3 botulinum toxin sub-
strate 1. Subsequently, podocyte effacement and pro-
teinuric disease is responsible.9,11,44 Recently, we
showed in this cohort that suPAR levels were highly
predictive of decline in kidney function and incident
CKD, even in patients with normal kidney function at
baseline.7 The role of suPAR in renal disease thus ap-
pears to go beyond focal segmental glomerulosclerosis,
although it might be related to different pathophysio-
logic mechanisms involving its different isoforms and
potentially both its proteolytic and signaling func-
tions.8,13,15,44,45 Further studies are needed in humans
to elucidate these mechanisms and identify potential
therapies modulating the suPAR pathway.
Our study was strengthened by the large sample size
and a well-characterized cohort with long follow-up
duration and availability of multiple eGFR measure-
ments. Unfortunately, follow-up proteinuria data were
lacking, and speciﬁc diagnoses of kidney disease were
not available. Thus, although we did not identify an
association between hs-TnI, hs-CRP, FDPs, and HSP-70
and a decline in renal function, we were unable to
make deﬁnite conclusions on associations with speciﬁc
kidney diseases nor exclude confounding by the
occurrence of contrast-induced nephropathy. More-
over, the cohort consisted of a highly select population
with CVD that underwent cardiac catheterization;
therefore, conclusions could not be generalized.
Nevertheless, the present study complemented our
previous ﬁnding of the association of suPAR with
incident kidney disease, and highlighted that the as-
sociation is independent of other markers of inﬂam-
mation and CVD.
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Table 4. Independent predictors of glomerular ﬁltration rate decline
Variables
eGFR (ml/min per kg/m2)
b 95% CI P value
Model 1: Clinical characteristics
Age, per 10 yr L0.89 L1.77 to L0.01 0.050
Male 0.21 2.02 to 2.44 0.85
African American 1.24 4.64 to 2.16 0.48
Body mass index, per 5 kg/m2 increase 0.31 0.52 to 1.13 0.47
Smoking history 0.36 1.58 to 2.30 0.72
Hypertension 0.32 2.65 to 2.02 0.79
Diabetes mellitus L3.87 L5.72 to L2.01 <0.001
Low-density lipoprotein, per 10 mg/dl 0.03 0.28 to 0.23 0.84
High-density lipoprotein, per 10 mg/dl 0.46 0.38 to 1.30 0.29
Myocardial infarction history 0.93 2.87 to 1.00 0.35
Revascularization history 2.28 0.06 to 4.49 0.040
Obstructive coronary artery disease 1.00 3.81 to 1.80 0.48
Heart failure L3.89 L5.91 to L1.87 0.002
ACEi/ARB use 2.57 0.75 to 4.40 0.01
Baseline eGFR, per 10 ml/min
per 1.73 m2
7.18 6.73 to 7.64 <0.001
Follow-up time, per year L1.25 L1.46 to L1.04 <0.001
Model 26: Clinical
characteristics þ individual biomarkers
SuPAR, per 100% increasefollow-up
time
L0.46 L0.84 to L0.08 0.02
Hs-CRP, per 100% increasefollow-up
time
0.04 0.15 to 0.07 0.46
FDP, per 100% increasefollow-up
time
0.13 0.27 to 0.01 0.08
HSP-70 > 1 ng/mlfollow-up time 0.05 0.47 to 0.58 0.84
Hs-TnI, per 100% increasefollow-up
time
0.01 0.09 to 0.06 0.76
Model 7: Clinical characteristics þ suPAR
adjusting for other biomarker levels
SuPAR, per 100% increasefollow-up
time
L0.44 L0.83 to L0.07 0.02
Biomarkers were each entered into separate models incorporating demographics and
risk factors. The estimate and CIs reported for the demographics and clinical charac-
teristics are derived from the model not incorporating any biomarkers. Statistically
signiﬁcant values at P < 0.05 are highlighted in bold.
ACEi, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, conﬁ-
dence interval; eGFR, estimated glomerular ﬁltration rate; FDP, ﬁbrin degradation
product; Hs-CRP, high-sensitivity C-reactive protein; HSP-70, heat shock protein 70; hs-
TnI, high-sensitivity troponin I; suPAR, soluble urokinase-type plasminogen activator
receptor.
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SUPPLEMENTARY MATERIAL
Figure S1. Association between soluble urokinase-type
plasminogen activator receptor (suPAR), high-sensitivity
C-reactive protein (hs-CRP), heat shock protein 70 (HSP-
70), ﬁbrin-degradation products (FDPs), and high-
sensitivity troponin I (hs-TnI) plasma levels and change
in estimated glomerular ﬁltration rate (eGFR0 during
follow-up in patients with at least 1 additional measure of
eGFR.
Supplementary material is linked to the online version of
the paper at http://www.kireports.org.
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